Invex Therapeutics Ltd. announced the publication of the Invex Phase II 'Pressure' clinical trial, which provided initial safety and efficacy of Exenatide in Idiopathic Intracranial Hypertension (IIH) patients. The publication titled "The effect of GLP-1RA exenatide on Idiopathic Intracanial Hypertension: Randomised Clinical Trial" was co-authored by Professor Alex Sinclair, Invex's Executive Director and Chief Scientific Officer; and Professor of Neurology in the Institute of Metabolism and Systems Research at the University of Birmingham, Honorary Consultant Neurologist at University Hospitals Birmingham NHS Foundation Trust, and Principal Investigator of the Pressure study. The Pressure trial was a double-blind, placebo controlled clinical trial of twice per day Exenatide versus placebo in the treatment of IIH.

The primary endpoint of the study was the change in intracranial pressure at 2.5hrs, 24hrs and 12 weeks post drug administration as measured by real-time patient monitoring devices. Secondary outcomes included monthly headache days, headache severity and monthly analgesia days and visual acuity.